Loading…
SBI Pharma Fund
Disclosed for 2 months, Nov 2013 to Dec 2013. This scheme is no longer reporting.
Portfolio value
₹148 Cr
Nov 2013
- Stocks held
- 17
- Top 10 weight
- 86.5%
- of the portfolio in its ten largest
- Cash & debt
- 1.8%
- cash, money market and debt
- Moves this month
- —
- no earlier month
SBI Pharma Fund is an active equity fund in the Sectoral / Thematic category from SBI Mutual Fund. In November 2013 it disclosed 17 stocks worth ₹148 Cr. Its largest positions were Sun Pharmaceutical Industries Limited (25.0%), Dr. Reddy's Laboratories Limited (16.7%), Lupin Limited (11.0%); the ten largest together made up 86.5% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 93.6% of its equity. Cash and debt stood at 1.8%.
Against 230 other Sectoral / Thematic funds
Concentration
99%
Top-10 weight is higher than 99% of peers
Breadth
4%
Holds more stocks than 4% of peers
Cash
27%
Holds more cash than 27% of peers
What these mean: concentration · cash
Holdings in November 2013
Download CSVEvery line the fund disclosed, with the change against the previous month. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 25.01% | — | ₹36.9 Cr | — | |
| Dr. Reddy's Laboratories Limited | 16.67% | — | ₹24.6 Cr | — | |
| Lupin Limited | 11.02% | — | ₹16.3 Cr | — | |
| Divi's Laboratories Limited | 6.08% | — | ₹9 Cr | — | |
| Glenmark Pharmaceuticals Limited | 5.94% | — | ₹8.8 Cr | — | |
| Cipla Limited | 5.30% | — | ₹7.8 Cr | — | |
| Aurobindo Pharma Limited | 4.98% | — | ₹7.3 Cr | — | |
| IPCA Laboratories Limited | 4.92% | — | ₹7.3 Cr | — | |
| Natco Pharma Limited | 3.69% | — | ₹5.4 Cr | — | |
| Strides Pharma Science Limited | 2.91% | — | ₹4.3 Cr | — | |
| Hikal Limited | 2.87% | — | ₹4.2 Cr | — | |
| Indoco Remedies Limited | 2.62% | — | ₹3.9 Cr | — | |
| Alembic Pharmaceuticals Limited | 2.08% | — | ₹3.1 Cr | — | |
| Torrent Pharmaceuticals Limited | 2.04% | — | ₹3 Cr | — | |
| Cash, TREPS & receivables | 1.83% | — | ₹2.7 Cr | — | |
| Procter & Gamble Health Limited | 1.27% | — | ₹1.9 Cr | — | |
| SHASUN PHARMACEUTICALS LTD. | 0.43% | — | ₹64 L | — | |
| Wyeth Ltd | 0.33% | — | ₹49 L | — |
What changed
This is the earliest month on record for the fund.
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
No earlier month with a sector split to compare against.
Allocation in Nov 2013
- Pharmaceuticals & Biotechnology (13)93.6%
- Pharmaceuticals (4)6.4%
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Nov 2013
1.8%
- Cash alone
- 1.8%
- cash and net receivables
- A year earlier
- —
- no disclosure
- Last 12 months
- —
- lowest to highest · record 1.8% in Nov 2013
Not enough months to draw.
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.